Subgroup and per-protocol analyses fromthe hypertension in the very elderly trial

Journal of Hypertension

Volumn 32, Issue 7, 2014, Pages 1478-1487

  Beckett, Nigel ^a   Peters, Ruth ^a   Leonetti, Gastone ^b   Duggan, Joe ^c   Fagard, Robert ^d   Thijs, Lut ^d   Narkiewicz, Krzysztof ^e   McCormack, Terry ^f   Banya, Winston ^a   Fletcher, Astrid ^g   Bulpitt, Christopher ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF MILAN   (Italy)

^c MATER PRIVATE HOSPITAL   (Ireland)

^d KU LEUVEN DEPARTMENT OF REHABILITATION SCIENCES   (Belgium)

^e UNIVERSITY OF GDA SK   (Poland)

^f Whitby Group Practice   (United Kingdom)

^g LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

Aged 80 and over; Clinical trial; Hypertension; Indapamide

Indexed keywords

INDAPAMIDE; PERINDOPRIL; PLACEBO; ANTIHYPERTENSIVE AGENT; DELAYED RELEASE FORMULATION; DRUG COMBINATION; INDAPAMIDE, PERINDOPRIL DRUG COMBINATION;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLINICAL PROTOCOL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; SUSTAINED DRUG RELEASE; SYSTOLIC BLOOD PRESSURE; VERY ELDERLY; AGE; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; DELAYED RELEASE FORMULATION; DRUG COMBINATION; DRUG EFFECTS; MORTALITY; MULTICENTER STUDY; PATHOPHYSIOLOGY; RISK ASSESSMENT; STROKE;

AGE FACTORS; AGED, 80 AND OVER; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DELAYED-ACTION PREPARATIONS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERTENSION; INDAPAMIDE; MALE; PERINDOPRIL; RISK ASSESSMENT; STROKE;

EID: 84903850252     PISSN: 02636352     EISSN: 14735598     Source Type: Journal    
DOI: 10.1097/HJH.0000000000000195     Document Type: Article

References (16)

1. Bulpitt C, Fletcher A, Beckett N, Coope J, Gil-Extremera B, Forette F, et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs Aging 2001; 18:151-164
2. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, et al. Treatment of hypertension in patients 80 years of age or older. N Engl J Med 2008; 358:1887-1898
3. Guidelines Subcommittee. World Health Organisation-International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 1999; 17:151-183
4. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, et al. 2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007; 25:1105- 1187
5. Gueyffier F, Bulpitt C, Boissel JP, Schron E, Ekbom T, Fagard R, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials. INDANA Group. Lancet 1999; 353:793- 796
6. Musini V, Tejani A, Bassett K, Wright J. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev 2009; CD000028
7. Beckett N, Peters R, Tuomilehto J, Swift C, Sever P, Potter J, et al., HYVET Study Group. Immediate and late benefits of treating very elderly people with hypertension: results from active treatment extension to Hypertension in the Very Elderly randomised controlled trial. BMJ 2012; 344:d7541
8. Lewington S, Clarke R, Qizilbash N, Peto R, Collins R. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360:1903-1913
9. Quan A, Kerlikowske K, Gueyffier F, Boissel JP. Efficacy of treating hypertension in women. J Gen Intern Med 1999; 14:718-729
10. Turnbull F, Woodward M, Neal B, Barzi F, Ninomiya T, Chalmers J, et al. Do men and women respond differently to blood pressurelowering treatment? Results of prospectively designed overviews of randomized trials. Eur Heart J 2008; 29:2669-2680
11. Gueyffier F, Boutitie F, Boissel JP, Pocock S, Coope J, Cutler J, et al. Effect of antihypertensive drug treatment on cardiovascular outcomes in women and men. A meta-analysis of individual patient data from randomized, controlled trials. The INDANA Investigators. Ann Intern Med 1997; 126:761-767
12. Safar ME, Smulyan H. Hypertension in women. Am J Hypertens 2004; 17:82-87
13. BMJ Clinical Evidence. Estimating CVD risk and treatment benefit. BMJ Clin Evidence 2007; http://www.clinicalevidence.com/ceweb/resour ces/men-no-diabetes.jsp#cvdChart
14. Pocock SJ, Assmann SE, Enos LE, Kasten LE. Subgroup analysis, covariate adjustment and baseline comparisons in clinical trial reporting: current practice and problems. Stat Med 2002; 21:2917-2930
15. Lagakos SW. The challenge of subgroup analyses: reporting without distorting. N Engl J Med 2006; 354:1667-1669
16. Freemantle N. Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? Br Med J 2001; 322:989-991.